Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Continuing to feel sick after two to three days on azithromycin is sometimes expected, but it can also point to a resistant bacterial infection, a viral illness the antibiotic cannot treat, or a more serious problem such as pneumonia. Red flags that warrant prompt medical attention include fever above 102°F, chest pain, shortness of breath, coughing up blood or thick discolored mucus, confusion, or symptoms that clearly worsen rather than improve after 72 hours. Several important factors change what this means for you, including the original diagnosis, your age, and whether you have asthma, COPD, diabetes, or a weakened immune system, so see below for the complete answer and details you should consider before waiting it out.
Because "not getting better" can mean anything from a slow-healing sinus infection to walking pneumonia, the fastest way to sort out low-risk from urgent is to describe your symptoms in a structured way. A free, instant online symptom check takes only a few minutes, asks the same follow-up questions a clinician would, and helps you decide whether to call your prescriber, seek same-day care, or keep monitoring at home.
Last reviewed for medical accuracy: 09/13/2026
It can be worrying if you’re on azithromycin but still feeling unwell. While azithromycin is a commonly prescribed antibiotic for a range of respiratory and other infections, lack of improvement doesn’t always mean you have pneumonia—or something life-threatening. Below, we’ll explore why azithromycin sometimes fails, how to recognize signs of a more serious illness, and what steps you can take next.
Azithromycin is a macrolide antibiotic that works by stopping bacteria from growing. It’s widely used to treat:
Key points about azithromycin:
If symptoms persist despite taking azithromycin as directed, consider these possibilities:
Pneumonia is an infection of the lung’s air sacs (alveoli). Antibiotics like azithromycin are frontline for community-acquired cases. Yet:
Symptoms suggesting pneumonia include:
If you have these, pneumonia is possible—and you should seek medical evaluation.
Whether or not you’re on azithromycin, get urgent help if you experience:
These could indicate a serious infection or complication that needs prompt attention.
Review Adherence
Consider Alternative Diagnoses
Diagnostic Testing
Symptom Monitoring
Get a Second Opinion or Specialist Referral
It’s normal to feel uneasy when treatment doesn’t work as expected. You don’t have to navigate this alone:
While you and your provider sort out the best treatment, focus on general measures that help any respiratory infection:
Not improving on azithromycin does not automatically mean serious disease—but it does warrant a closer look:
Always remember: your health is unique. If you experience any concerning signs or simply feel something isn’t right, don’t wait. Speak to a healthcare professional—your doctor can adjust treatment, order tests, or refer you for specialized care.
If you think you might have a serious infection or pneumonia, please speak to a doctor right away. Your wellbeing is too important to leave to chance.
(References)
* Toyonaga Y, Ishihara T, Nakamura H. [Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients]. Jpn J Antibiot. 1996 Nov;49(11):981-93. PMID: 8988410.
* Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother. 1998 Feb;10(1):64-8. doi: 10.1179/joc.1998.10.1.64. PMID: 9531077.
* Liu YL, Wu PS, Tsai LP, Tsai WH. Pediatric round pneumonia. Pediatr Neonatol. 2014 Dec;55(6):491-4. doi: 10.1016/j.pedneo.2013.01.014. Epub 2013 Mar 13. PMID: 23597522; PMCID: PMC7102776.
* Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K, Yang JB, Huang X, Tang BH, Chen XK, Shi HY, Zhou Y, Wu YE, Qi H, Jacqz-Aigrain E, Shen AD, Zhao W. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. Antimicrob Agents Chemother. 2018 Sep;62(9). doi: 10.1128/AAC.00686-18. Epub 2018 Aug 27. PMID: 29941652; PMCID: PMC6125566.
* Firth A, Prathapan P. Azithromycin: The First Broad-spectrum Therapeutic. Eur J Med Chem. 2020 Dec 1;207:112739. doi: 10.1016/j.ejmech.2020.112739. Epub 2020 Aug 19. PMID: 32871342; PMCID: PMC7434625.
* RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5. Epub 2021 Feb 2. PMID: 33545096; PMCID: PMC7884931.
* Qian S, Siu J, Hussein A, Zheng Y. Appropriate prescribing of azithromycin for community-acquired pneumonia. Intern Med J. 2022 Jun;52(6):1079-1082. doi: 10.1111/imj.15810. Epub 2022 May 24. PMID: 35608398; PMCID: PMC9322330.
* Wang Z, Chu C, Ding Y, Li Y, Lu C. Clinical significance of serum microRNA-146a and inflammatory factors in children with Mycoplasma pneumoniae pneumonia after azithromycin treatment. J Pediatr (Rio J). 2024 Jan-Feb;100(1):108-115. doi: 10.1016/j.jped.2023.06.004. Epub 2023 Sep 28. PMID: 37778397; PMCID: PMC10751685.
* Leroy AG, Caillon J, Broquet A, Lemabecque V, Delanou S, Caroff N, Asehnoune K, Roquilly A, Crémet L. Azithromycin regulates bacterial virulence and immune response in a murine model of ceftazidime-treated Pseudomonas aeruginosa acute pneumonia. Microbiol Immunol. 2024 Feb;68(2):27-35. doi: 10.1111/1348-0421.13106. Epub 2023 Dec 10. PMID: 38073281.
* Glascock A, Maguire C, Phan HV, Lydon EC, Schaenman J, Calfee CS, Melamed E, Greenland J, Corry DB, Kheradmand F, Baden LR, Sekaly R, McComsey GA, Haddad EK, Cairns CB, Geng LN, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf JP, Agudelo Higuita NI, Messer WB, Davis MM, Nadeau KC, Kraft M, Bime C, Erle DJ, Atkinson MA, Brakenridge SC, Ehrlich LIR, Montgomery RR, Shaw AC, Hough CL, Hafler DA, Augustine AD, Becker PM, Peters B, Ozonoff A, Hoch A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman MC, Wilson M, Guan L, Maecker H, Steen H, IMPACC Network, Diray-Arce J, Rouphael N, Kleinstein SH, Jayavelu ND, Reed EF, Levy O, Chu VT, Langelier CR. Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19. Nat Microbiol. 2026 Apr;11(4):1100-1112. doi: 10.1038/s41564-026-02285-8. Epub 2026 Mar 16. PMID: 41840216; PMCID: PMC13056551.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.